SiNtx TechnologiesSINT
SINT
About: SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.
Employees: 20
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
86% more capital invested
Capital invested by funds: $279K [Q1] → $519K (+$240K) [Q2]
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
7% more funds holding
Funds holding: 14 [Q1] → 15 (+1) [Q2]
2.3% more ownership
Funds ownership: 4.16% [Q1] → 6.46% (+2.3%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$28
709%
upside
Avg. target
$28
709%
upside
High target
$28
709%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo | 709%upside $28 | Buy Maintained | 30 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
SINTX Technologies Issues Business Update Following Strategic Realignment, Leadership Expansion, and SiNAPTIC Acquisition
Company Reinforces Commercialization Focus and Strategic Direction SALT LAKE CITY, Utah, Aug. 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical device applications, today issued a business update in connection with the filing of the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the Securities and Exchange Commission and available at www.sec.gov. The business update highlights meaningful progress from the Company's recent SiNAPTIC acquisition, decisive strategic transformation, and a revitalized commercialization strategy aimed at accelerating growth over the next twelve to twenty-four months.
Neutral
GlobeNewsWire
3 weeks ago
SINTX Technologies Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates
SALT LAKE CITY, Utah, Aug. 04, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for musculoskeletal applications, today announced the publication of a peer-reviewed study in the Journal of the Mechanical Behavior of Biomedical Materials. The study validates the use of silicon nitride (Si₃N₄) surface coatings on carbon fiber–reinforced polyetherketoneketone (CFR-PEKK) trauma plates—marking a significant expansion of SINTX's biomaterial platform into additively-manufactured polymer-carbon-ceramic constructs.
Neutral
GlobeNewsWire
2 months ago
SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market
Strategic Acquisition Brings Patented Implant Designs, Seasoned Executive Team, and Near-Term Commercial Opportunities
Neutral
GlobeNewsWire
3 months ago
SINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market
SALT LAKE CITY, Utah, May 22, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramics for medical device and other technical applications, announced the issuance of International Patent No. 7635292, which covers novel agricultural uses of the Company's silicon nitride (Si₃N₄) particularly in plant protection and antimicrobial treatment. This patent, combined with issued U.S. Patent No. 11,591,217, creates a family of patents focused on addressing the antimicrobial agribiotech market.
Neutral
GlobeNewsWire
3 months ago
SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization
Salt Lake City, UT , May 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT), an advanced ceramics company pioneering medical and antipathogenic applications of silicon nitride (Si₃N₄), today provided a comprehensive update on its operational progress, strategic initiatives, and financial position for the first quarter ended March 31, 2025.
Neutral
GlobeNewsWire
5 months ago
SINTX Technologies Announces $5 Million Private Placement Priced At-the-Market under Nasdaq Rules
Salt Lake City, Utah, Feb. 26, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc., (“SINTX” or the “Company”) (Nasdaq: SINT), a leader in advanced ceramics for medical applications, today announced that it has, pursuant to a securities purchase agreement with institutional and accredited investors dated February 20, 2025, issued and sold 1,449,287 shares of common stock (or pre-funded warrants in lieu therof) at a purchase price of $3.45 per share (or pre-funded warrant in lieu thereof) in a private placement priced at-the-market under Nasdaq rules. In addition, the Company issued to the investors in the offering unregistered warrants (the “warrants”) to purchase up to an aggregate of 1,449,287 shares of common stock.
Neutral
GlobeNewsWire
6 months ago
SINTX Technologies Sells Technology Assesment and Transfer Subsidiary to Focus on Medical Device Market
Strategic Transaction Enhances Financial Flexibility and Supports Growth in Healthcare Innovations Salt Lake City, UT, Feb. 20, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT), a leader in advanced ceramics for medical applications, today announced the sale of its wholly-owned subsidiary, Technology Assessment and Transfer (TA&T), to Tethon Corporation DBA Tethon 3D (Tethon). This transaction marks a significant step in SINTX's ongoing transformation, allowing the Company to sharpen its focus on high-growth opportunities in the medical device sector while improving its financial position and operational efficiency.
Neutral
GlobeNewsWire
6 months ago
SINTX Receives Issuance of U.S. Patent for Silicon Nitride-Functionalized Zirconia-Toughened Alumina Ceramic Biomaterial
Salt Lake City, Utah, Feb. 19, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”) an advanced ceramics company specializing in the development and commercialization of materials, components, and technologies for medical and technical applications, today announced the issuance of U.S. Patent No. 12,239,761 by the United States Patent and Trademark Office (USPTO).
Neutral
GlobeNewsWire
9 months ago
SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment
Salt Lake City, UT, Nov. 21, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, announces the signing of a Joint Development Agreement (JDA) with NED Medical Inc., an innovative developer of oncology embolization therapy technologies. This collaboration aims to accelerate the development of advanced ceramic-based microspheres, a groundbreaking advancement in radiotherapeutic applications.
Neutral
GlobeNewsWire
9 months ago
SINTX Technologies Appoints Gregg R. Honigblum as Chief Strategy Officer
Seasoned Healthcare Executive to Lead Strategic Growth Initiatives Salt Lake City, UT, Nov. 19, 2024 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications, is pleased to announce the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO).
Charts implemented using Lightweight Charts™